Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, complet | Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former ...

R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

PHILADELPHIA, PA — Imvax, Inc, recently closed a $29 million financing round from existing investors. This marks the latest milestone in the company’s fundraising efforts, which have totaled $86 ...

Beyond called off its $40 million investment deal with The Container Store. The parent company of Bed, Bath and Beyond in November cast doubt on the deal, expressing concerns the specialty retailer ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

Staunton's Thomas Chisley broke a 24-year-old track and field record. Hanger leads Fort boys. A look at the Region 2B playoff standings for boys and girls.

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Topline results were announced from a phase 2/3 trial evaluating linsitinib for the treatment of moderate to severe thyroid eye disease.

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participan ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...

MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...